Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran
Abstract
Background and Objectives: Hepatitis C Virus genotyping appears to be vital for predicting the response to antiviral therapy. The present study aimed to analyze the HCV genotypes in relation to persistence or clearance of the virus in residents of Hamadan Province, West-Iran.
Material and Methods: A total of 1159 recorded questionnaires of HCV infected people were evaluated in this prospective study. Several parameters including HCV genotypes, anti-HCV antibodies, viral load, drug treatment, response to therapy and amount of ALT and AST were analyzed.
Results: HCV genotyping in 637 samples revealed a predominance of type 1a (52.1%) followed by 3a (42.4%), type 1b (2.7%) and type 2 (0.2%) respectively. Mixed genotypes (3a-1a) were detected in 0.9%, and 1.7% had untypable genotype. High frequency of genotypes 1a and 3a were observed in drug-resistant (group-a) and drug-sensitive (group-b) patients respectively (P<0.0001). Additionally, duration of drug treatment was significantly higher in group-a than group-b (P<0.0001). During follow-up period, 92 cases showed spontaneous clearance of HCV infection and more importantly 86 of 92 cases were positive for anti-HCV antibodies compared with 59 of 455 antibody positive cases with treatment-induced clearance of HCV infection (P<0.0001).
Conclusion: HCV genotyping and also antibody screening could be useful for proper therapeutic intervention in HCV infected subjects.
Attaullah S, Khan S, Ali I. Hepatitis c virus genotypes in pakistan: A systemic review. Virol J 2011;8:433.
Howard CR. Hepatitis c virus: Clades and properties. J Gastroenterol Hepatol 2002;17 Suppl:S468-470.
Ripoli M, Pazienza V. Impact of hcv genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther 2011;9:747-759.
Rolfe KJ, Curran MD, Alexander GJ, Woodall T, Andrews N, Harris HE. Spontaneous loss of hepatitis c virus rna from serum is associated with genotype 1 and younger age at exposure. J Med Virol 2011;83:1338-1344.
Guido M, Rugge M, Thung SN, Chemello L, Leandro G, Alberti A, et al. Hepatitis c virus serotypes and liver pathology. Liver 1996;16:353-357.
Nakamura H, Kako M, Aikawa T, Mayumi M, Kanai K. [HCV-serotype and ifn response]. Nihon Rinsho 1994;52:1734-1737.
Moatter T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S. Comparative analysis of viral titers and histologic features of pakistani patients infected with hepatitis c virus type 3. Int J Infect Dis 2002;6:272-276.
Keyvani H, Alizadeh AH, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis c virusgenotypes in 2231 patients in iran. Hepatol Res 2007;37:101-103.
Kabir A, Alavian SM, Keyvani H. Distribution of hepatitis c virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: A preliminary study. Comp Hepatol 2006;5:4.
Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepatitis Monthly 2013;13(1):e7991.
Vahdat K, Keyvani H, Tabib SM, Rostamabadi S, Valizadeh SM, Cheraghi S, Shamsian S, Zandi K. Molecular epidemiology of hepatitis c virus genotypes in Bushehr province, Iran. Eur Rev Med Pharmacol Sci 2010;14:861-864.
Feyznezhad R, Behzadi MA, Yaghobi R, Ziyaeyan M. Determining major genotypes of hepatitis C virus among transplant recipients by real-time polymerase chain reaction assay. Jundishapur J Microbiol 2015;8(2):e16722.
Salehi Moghadam F, Mohebbi SR, Hosseini SM, Romani S, Mirtalebi H, Azimzadeh P, et al. Phylogenetic analysis of hepatitis C virus strains and risk factors associated with infection and viral subtypes among Iranian patients. J Med Virol 2014;86: 1342-49.
Sunbul M, Khan A, Kurbanov F, Leblebicioglu H, Sugiyama M, Tanaka Y, et al. Tracing the spread of hepatitis c virus in turkey: A phylogenetic analysis. Intervirology 2013;56:201-205.
Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis c virus in iran as reflected by phylogenetic analysis of the ns5b region. J Med Virol 2004;74:246-252.
Taha AA, El-Ray A, El-Ghannam M, Mounir B.Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010;24:597-602.
Cavalheiro Nde P, Barone AA, Tengan FM. HCV sero types in brazilian patients. Int J Infect Dis 2002;6:228-232.
De Cock L, Vranckx R. Serotyping and genotyping of hepatitis c virus in Belgium. Infection 2003;31:92-97.
Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck- Ytter Y, et al. U.S. Multicenter pilot study of daily csensus interferon (cifn) plus rib avirin for "Diff- cult-to-treat" Hcv genotype 1 patients. Dig Dis Sci 2011;56:880-888.
Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC.Influence of MHC class II genotype on outcome of in fection with hepatitis c virus. The hencore group. Hep atitis c european network for cooperative research. Lan cet 1999;354:2119-2124.
Yoon SK, Han JY, Pyo CW, Yang JM, Jang JW, Kim CW, et al. Association between human leuko cytes antigen alleles and chronic hepatitis c virus ifeti- on in the korean population. Liver International 2005; 25:1122-1127.
Matsumori A. Role of hepatitis c virus in cardiomyop athies . Ernst Schering Res Found Workshop 2006:99-120.
Shichi D, Matsumori A, Naruse TK, Inoko H, Kimura A. HLA-DQB chain may confer the susceptibility to hep- atitis c virus-associated hypertrophic cardiomyopathy.Int J Immunogenetics 2008;35:37-43.
Fanning LJ, Levis J, Kenny-Walsh E, Whelton M,O'Sullivan K, Shanahan F. HLA class II genes determine the natural variance of hepatitis c viral load. Hepatology 2001;33:224-230.
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepa- titis c virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.
| Files | ||
| Issue | Vol 7 No 2 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| Epidemiology Genotype HCV Antibody | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
